Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other financing activities (2016 - 2024)

Ani Pharmaceuticals (ANIP) has disclosed Other financing activities for 11 consecutive years, with $2.0 million as the latest value for Q4 2024.

  • Quarterly Other financing activities changed N/A to $2.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, down 19.63% year-over-year, with the annual reading at $17.4 million for FY2024, N/A changed from the prior year.
  • Other financing activities hit $2.0 million in Q4 2024 for Ani Pharmaceuticals, up from $483000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $13.6 million in Q4 2021 to a low of -$449000.0 in Q3 2020.
  • Historically, Other financing activities has averaged $1.7 million across 4 years, with a median of $309000.0 in 2020.
  • Biggest five-year swings in Other financing activities: tumbled 437.59% in 2020 and later surged 2105.83% in 2021.
  • Year by year, Other financing activities stood at $618000.0 in 2020, then soared by 2105.83% to $13.6 million in 2021, then tumbled by 96.46% to $483000.0 in 2022, then skyrocketed by 309.32% to $2.0 million in 2024.
  • Business Quant data shows Other financing activities for ANIP at $2.0 million in Q4 2024, $483000.0 in Q3 2022, and $203000.0 in Q2 2022.